Loading stock data…
$8.42-0.14 (-1.69%)
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.
Contineum Therapeutics, Inc. in the Healthcare sector is trading at $8.42 with a market capitalization of $545M. Wall Street consensus targets $21.29 (7 analysts), implying a +152.8% move over the next 12 months. The stock is currently near its 52-week low of $8.10, remaining 38.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$17.43M↓ | -$16.90M↑ | -$17.11M↓ | -$14.93M↑ | -$17.90M |
| Net Income | -$15.15M↓ | -$14.46M↑ | -$15.16M↓ | -$12.79M↑ | -$16.04M |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-7...